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Abstract: Urolithin A is a metabolite generated from ellagic acid and ellagitannins by the intestinal
microbiota after consumption of fruits such as pomegranates or strawberries. The objective of this
study was to determine the cytoprotective capacity of this polyphenol in Neuro-2a cells subjected
to oxidative stress, as well as its direct radical scavenging activity and properties as an inhibitor
of oxidases. Cells treated with this compound and H2O2 showed a greater response to oxidative
stress than cells only treated with H2O2, as mitochondrial activity (MTT assay), redox state (ROS
formation, lipid peroxidation), and the activity of antioxidant enzymes (CAT: catalase, SOD: superoxide
dismutase, GR: glutathione reductase, GPx: glutathione peroxidase) were significantly ameliorated;
additionally, urolithin A enhanced the expression of cytoprotective peroxiredoxins 1 and 3. Urolithin
A also acted as a direct radical scavenger, showing values of 13.2 µM Trolox Equivalents for Oxygen
Radical Absorbance Capacity (ORAC) and 5.01 µM and 152.66 µM IC50 values for superoxide and
2,2-diphenyss1-picrylhydrazyl (DPPH) radicals, respectively. Finally, inhibition of oxidizing enzymes,
such as monoamine oxidase A and tyrosinase, was also detected in a dose-dependent manner.
The cytoprotective effects of urolithin A could be attributed to the improvement of the cellular
antioxidant battery, but also to its role as a direct radical scavenger and enzyme inhibitor of oxidases.
Keywords: urolithin A; pomegranate; ellagic acid; dietary polyphenols; neuroprotection; peroxiredoxins
1. Introduction
Urolithins are natural polyphenolic compounds obtained from ellagic acids and ellagitannins
by the gut microbiota. Ellagic acid is a phenolic antioxidant compound present in numerous fruits,
such as pomegranates, strawberries, or nuts. Ellagitannins are a class of polymeric ellagic acid
derivatives also present in pomegranates (punicalagins and punicalins) and other sources, such as oak
or chestnut wood (castalagin, castalin, roburin A, grandinin) or Melaleuca quinquenervia leaves (castalin
and grandinin) [1–3].
The beneficial properties of these plants and foods seem to be in relation with these polyphenolic
metabolites; however, the metabolism of polyphenols from food seems to be insufficient to achieve
adequate levels of urolithins in the body. In addition, it has been proven that apparently beneficial
foods such as pomegranates have had a lot of interindividual variability due to the different urolithin
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metabotypes present in the population [4]. In fact, only 1 in 3 people have the right microbiota to
perform this metabolism with maximum efficiency [5].
Therefore, it is very important to evaluate the activity of isolated urolithins as potential therapeutic
agents. In addition, the use if urolithin A in humans and the safety profile of this compound have been
widely evaluated, with no adverse effects on health observed [6].
Although urolithins are a group of metabolites, urolithin A (UA), also known as
3,8-dihydroxyurolithin, is one of the most representative compounds. There are numerous studies that
demonstrate an important role of this compound in metabolic syndrome, improving cardiovascular
function, decreasing the formation of triglycerides, inhibiting enzymes such as lipase or glucosidase,
or relieving insulin resistance [7–9]. It has also been observed that UA may have an important role
in the prevention of certain cancers, such as colorectal or prostate cancers [10,11]. UA also has an
important role at the mitochondrial level, being able to activate mitophagy and prolonging lifespan in
Caenorhabditis elegans worms, as well as beneficial mitochondrial effects in the skeletal muscle [12,13].
The set of all these beneficial properties for health may be due to the antioxidant capacity of
polyphenols. However, there are few studies that link the antioxidant properties of this metabolite
with a potential therapeutic activity in neurodegenerative diseases, where the redox status is essential.
Therefore, the objective of this study was to evaluate whether urolithin A has antioxidant and
neuroprotective effects using Neuro-2a cells and other in vitro models involving the use of central
nervous system (CNS) enzymes or free radicals.
2. Materials and Methods
2.1. Reagents and Chemicals
Urolithin A (3,8-dihydroxyurolithin) (Figure 1) was purchased from Toronto Research Chemicals
(TRC, Toronto, ON, Canada). Neuro-2a (N2a) cell line was provided from the American
Type Culture Collection (ATCC, Manassas, VA, USA), while Monoamine oxidase A (MAO-A),
5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB), Tris, galantamine, levodopa (l-DOPA), tyramine,
horseradish peroxidase, 2,2′-azobis(2-methyl-propionamidine)-di-hydrochloride (AAPH), hydrogen
peroxide (30% w/w), 2,4,6-Tris(2-pyridyl)-1,3,5-triazine (TPTZ), 2′,7′-dichloro-dihy-drofluorescein
diacetate (DCFH-DA), 3-(4,5-Dimethyl-2-thiazolyl)-2,5- diphenyltetrazolium bromide (MTT),
6-hydroxy-2,5,7,8-tetra-methylchromane-2-carboxylic acid (Trolox), bovine serum albumin (BSA),
vanillic acid, 4-aminoantipyrine, penicillin, streptomycin, tyrosinase, thiobarbituric acid (TBA),
trichloroacetic acid (TCA), bicinchoninic acid (BCA), and pyrogallol were obtained from Sigma-Aldrich
(Madrid, Spain). Clorgyline and α-kojic were from Cymit química (Barcelona, Spain). Na2CO3, HCl,
NaCl, dimethyl sulfoxide (DMSO), MeOH, and potassium phosphate were supplied from Panreac
(Barcelona, Spain). Dulbecco’s modified Eagle’s medium (DMEM), phosphate-buffered saline (PBS),
and fetal bovine serum (FBS) were acquired from Gibco (Invitrogen, Paisley, UK).
Antioxidants 2019, 8, x FOR PEER REVIEW 2 of 16 
metabotypes present in the population [4]. In fact, only 1 in 3 people have the right microbiota to 
perform this metabolism with maximum efficiency [5]. 
Therefore, it is very important to evaluate the activity of isolated urolithins as potential 
therapeutic agents. In addition, the use if urolithin A in humans and the safety profile of this 
compou d have been widely evaluated, with no adverse effects on health observed [6].  
Although urolit i s are a group of metabolites, urolithin A (UA), also known as 3,8-
dihydroxy rolithin, is o e of the most representative compounds. There are numerous studies that 
demonstrate an important role of this compound in metabolic syndrome, improving cardiovascular 
function, decreasing the formation of triglycerides, inhibiting enzymes such as lipase or glucosidase, 
or relieving insuli  resistance [7–9]. It has also been observed that UA may ave an important role in 
the prevention of certain cancers, suc  as colorectal or prostate cancers [10,11]. UA also has an 
important role at the mitochondrial level, being able to activate mitophagy and prolonging lifespan 
in Caenorhabditis elegans worms, as well as beneficial mitochondrial effects in the skeletal muscle 
[12,13]. 
he set of all these beneficial ro erties for health ay be e to the antioxi ant ca acity of 
oly henols. o ever, there are fe  st ies that link the antioxi ant ro erties of this etabolite 
ith a potential therapeutic activity in neurodegenerative diseases, where the redox status is 
essential. Therefore, the objective of this study was to evaluate whether urolithin A has antioxidant 
and neuroprotective effects using Neuro-2a cells and other in vitro models involving the use of 
central nervous system (CNS) enzymes or free radicals. 
     
2.1. Reagents and Che icals 
rolithin A (3,8-dihydroxyurolithin) (Figure 1) was purchased from Toronto Research 
Chemicals (TRC, Toronto, ON, Canada). Neuro-2a (N2a) cell line was provided from the erican 
Type Culture Collection (ATCC, Manassas, VA, USA), while Monoamine oxidase A (MAO- ), 5,5′-
dithiobis-(2-nitrobenzoic acid) (DTNB), Tris, galantamine, levodopa (L-DOPA), tyra ine, 
horseradish peroxidase, 2,2′-azobis(2- ethyl-propiona idine)-di-hydrochloride ( P ), hydrogen 
peroxide (30  w/w), 2,4,6-Tris(2-pyridyl)-1,3,5-triazine (TPTZ), 2′,7′-dichloro-dihy-drofluorescein 
diacetate ( CF -DA), 3-(4,5-Dimethyl-2-thiazolyl)-2,5- diphenyltetrazolium bromide (MTT), 6-
hydroxy-2,5,7,8-tetra-methylchromane-2-carboxylic acid (Trolox), bovine serum albu in (BS ), 
vanillic acid, 4-a inoantipyrine, penicillin, strepto ycin, tyrosinase, thiobarbituric acid (TB ), 
trichloroacetic acid (TCA), bicinchoninic acid (BCA), and pyrogallol were obtained from Sigma-
Aldrich (Madrid, Spain). Clorgyline and α-kojic were fro  Cymit química (Barcelona, Spain). 
a2CO3, HCl, NaCl, dimethyl sulfoxide (DMSO), MeOH, and potassium phosphate were supplied 
from Panreac (Barcelona, Spain). Dulbecco’s modified Eagle’s medium (DMEM), phosphate-buffered 
saline (PBS), and fetal bovine serum (FBS) were acquired from Gibco (Invitrogen, Paisley, UK). 
 
 
 
Figure 1. Structure of Urolithin A. Synonyms: 3,8-Dihydroxyurolithin; 3,8-Hydroxydibenzo-α-
pyrone; 2′,7-Dihydroxy-3,4-benzocoumarin; δ-Lactone 2′,4,4′-Trihydroxy-2-biphenylcarboxylic acid. 
Figure 1. Structure of Urolithin A. Synonyms: 3,8-Dihydroxyurolithin; 3,8-Hydroxydibenzo-α-pyrone;
2′,7-Dihydroxy-3,4-benzocoumarin; δ-Lactone 2′,4,4′-Trihydroxy-2-biphenylcarboxylic acid.
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2.2. Cytoprotective Properties of Urolithin A in Neuro-2a Cells
2.2.1. Neuro-2a Cell Culture and Treatments with Urolithin A and Hydrogen Peroxide
Neuro-2a cells (ATCC® CCL-131™) were thawed and cultured in 10% FBS-supplemented DMEM
and 1% penicillin-streptomycin, seeded in a T175 flask, and placed into the incubator (5% CO2, 37 ◦C).
Once they reached the state of confluence, they were sub-cultured in a 96-well plate at a density of 1 ×
104 cells/well in DMEM (10%) and incubated (37 ◦C, 5% CO2) for 24 h before the treatment.
Stock solutions of urolithin A (438 mM) were prepared in sterilized PBS containing 1% DMSO
(final concentration in the cells less than 0.1%). The sample was vortexed and filtered with a 0.22-µm
syringe filter. Five dilution series were done from the stock solution. Stock solutions of hydrogen
peroxide (1000 µM) were prepared and incorporated into the cells at a final concentration of 250 µM
(45 min) to induce oxidative stress in the cells.
2.2.2. Mitochondrial Activity in Neuro-2a Cells Subjected to Oxidative Stress after Urolithin A
Treatment
Cells were cultured in 96-well plates at a concentration of 1 × 104 cells per well. The cytotoxicity
of urolithin A (0.5 µM–20 µM) was measured after 24 h by adding MTT (3-(4,5-dimethylthiazol
-2-yl)-2,5-diphenyltetrazolium bromide) to the cell culture. Additionally, this assay can be performed
to assess the potential cytoprotective effect of urolithin A after inducing a neuronal injury with 250 µM
hydrogen peroxide for 45 min. After treatments (24 h exposition to urolithin, 45 min to hydrogen
peroxide), cells were incubated for an additional 24 h; DMEM was then removed from every well
and replaced with MTT solution (2 mg/mL in DMEM) and incubated at 37 ◦C for 3 h. Finally, MTT
solution was removed and 100 µL of DMSO was added in each well to dissolve formazan crystals. Via
a Synergy H1 Hybrid Multi-Mode Reader (Biotek, Bad Friedrichshall, Germany), the absorbance was
read at 550 nm. Experiments were carried out in different weeks and diverse passages and expressed
as percentage of control.
2.2.3. ROS Production in Neuro-2a Cells Subjected to Oxidative Stress after Exposition to Urolithin A
Neuro-2a cells were seeded in a 96-well plate. After 24 h, the medium was replaced with PBS
supplemented with glucose and DCFH-DA (2,7-di-chloro-dihydrofluorescein diacetate, 0.01 M) for
30 min at 37 ◦C. After this time, PBS was removed and cells were washed twice with new PBS and
treated with different concentrations of urolithin A (0.5–4 µM), as well as hydrogen peroxide (250 µM).
The absorbance was checked at 480 nm (λexcitation) and 520 nm (λemission) wavelengths [14]. The kinetic
was performed over 90 min in a Synergy H1 Hybrid Multi-Mode Reader (Winooski, VT, USA). Results
were represented as a percentage of intracellular ROS production (100% of control).
2.2.4. Lipid Peroxidation in Neuro-2a Cells Subjected to Oxidative Stress after Exposition to Urolithin
A (TBARS assay)
Lipid peroxidation was assessed using the protocol by Mitsuru Uchiyama [15]. First, 100 µL
of thawed pellets were placed into 200 µL of TBA–TCA–HCl cocktail and subsequently boiled at
100 ◦C for 10 min to accelerate the reaction. The reaction was broken by placing the samples on ice
and stunning them in a vortex three times for 20 min and centrifuged at 4 ◦C (3000 rpm, 10 min).
The obtained supernatant was placed in three different wells of a 96-well plate and absorbance was
read at 530 nm using a Synergy H1 Hybrid Multi-Mode Reader.
2.2.5. Activity of Antioxidant Enzymes in Neuro-2a Cells Subjected to Oxidative Stress after
Exposition to Urolithin A
Before analyzing the activity of antioxidant enzymes, the protein content of Neuro-2a cells was
calculated by colorimetric bicinchoninic acid (BCA) assay and normalized lysis buffer for 20 min
(Ethylenediaminetetraacetic acid (EDTA) 1 mM, Tris 25 mM, NaCl 150 mM and 0.1% Triton; pH = 7.4).
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Moreover, leupeptin, pepstatin, and phenylmethylsulfonyl fluoride (PMSF) proteinase inhibitors (20,
10, and 35 µL/mL, respectively) were aggregated into the buffer. Finally, supernatant was kept for the
experiments and the precipitate was discard.
The activity of catalase was measured as follows: hydrogen peroxide (1970 µL, 15 mM) was
prepared in sodium phosphate buffer (pH = 7.5) supplemented with 30 µL of supernatant [16]; the
mixture was prepared in a quartz cuvette, measuring the absorbance for 30 secs at 240 nm, using
a Shimadzu Spectrophotometer UV-1800 (Duisburg, Germany). The activity of the enzyme was
expressed following the next equation: Catalase activity = ((∆Abs/min) × 2 × F)/(0.0436 × Vs × C)
43.6 mL nmol−1 cm−1: molar extinction coefficient of H2O2
F: dilution factor
C: Protein concentration (mg/mL)
Vs: Sample volume (mL)
∆Abs/min: activity of the kinetic
For superoxide dismutase (SOD), a mixture of 1555 µL of Tris–DTPA buffer (50 mM, pH 8.2),
20 µL of pyrogallol (23.78 mM) diluted in HCl (10 mM), and 25 µL total cell extracts was placed in
a quartz cuvette to measure the oxidation of pyrogallol at 420 nm for 1 min [17], using a Shimadzu
Spectrophotometer UV-1800 (Duisburg, Germany). The activity of SOD was expressed with the
following equation: % Inhibition = (∆Abs control − ∆Abs sample)/(∆Abs control) × 100
SOD activity = (% Inhibition × 2 × F)/(50 × Vs × C)
Glutathione reductase activity (GR) was quantified with the protocol developed by Staal et al. [18]:
1180 µL of 50 mM phosphate buffer__EDTA (6.3 mM, pH 7.4), 50 µL of total cell extracts, 35 µL
of glutathione disulfide (GSSG) 5 mM, and 35 µL of nicotinamide adenine dinucleotide phosphate
(NADPH; 2.4 mM), which were mixed in a quartz cuvette. Glutathione peroxidase activity (GPx) was
detected by mixing 1220 µL of 50 mM phosphate buffer__EDTA 6.3 mM, 20 µL of total cell extracts,
and 20 µL of glutathione (GSH) 10 mM. After 5 min in dark conditions, 20 µL of NADPH (2.4 mM) and
20 µL H2O2 63.5 mM were added to the cuvette [19,20]. GR activity was read for three minutes with
60 sec of delay at 340 nm using a Shimadzu Spectrophotometer UV-1800 (Duisburg, Germany). GPx
activity was measured for 3 min at 340 nm and expressed in UI/mg protein. GR activity = ((∆Abs/min)
× 1.3 × F)/(0.00622 × Vs × C) GPx activity = ((∆Abs/min) × 1.3 × F)/(0.00622 × Vs × C)
0.00622 mL nmol−1 cm−1: molar extinction coefficient of NADPH
F: dilution factor
C: Protein concentration (mg/mL)
Vs: Sample volume (mL)
∆Abs/min: activity of the kinetic
2.2.6. Peroxiredoxin Expression in Neuro-2a Cells by Immunoblotting
In order to evaluate the effect of urolithin A on the expression of Prx1 and Prx3, Neuro-2a were
grown in 6-well culture plates and treated with 0.5–4 µM urolithin A for 24h. Twenty-four hours later,
cells were washed with PBS and scraped in lysis buffer (EDTA 1 mM, Tris 25 mM, NaCl 150 mM,
0.1% Triton; PMSF, leupeptin, and pepstatin; pH = 7.4) for 20 min. Supernatants were collected for
protein determination with the bicinconinc acid method and dilutions were prepared to obtain the
concentrations of proteins. Then, 10 µg of protein extract per sample was mixed with Laemmli buffer
with β-mercaptoethanol, loaded onto 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), and subsequently transferred to nitrocellulose membranes. Immediately after this, protein
transfer and loading were controlled by Ponceau red staining, followed by membrane blocking with
bovine serum albumin (BSA). The following antibodies were used: anti-Peroxiredoxin 1 (ab41906;
Abcam, Cambridge, UK) and anti-Peroxiredoxin 3 (AV52341; Sigma-Aldrich, St. Louis, MO, USA).
Antibody binding was detected by chemiluminescence with species-specific secondary antibodies
labeled with horseradish peroxidase (HRP) and visualized on a digital luminescent imager analyzer
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(Fujifilm LAS-4000, Cambridge, MA, USA). Images were quantified using ImageQuant TL software
(Global Life Sciences Solutions, Pittsburgh, PA, USA).
2.3. Urolithin A and Its Role as an Inhibitor of CNS Enzymatic Targets
2.3.1. Tyrosinase (TYR) Inhibition
Tyrosinase inhibitory activity of urolithin A was evaluated using 96-well plates and l-DOPA as
the substrate [21]. The α-Kojic acid was used as a reference inhibitor. The reaction mixture contained
10 µL of urolithin A at different concentrations in DMSO, 80 µL phosphate buffer (pH = 6.8), 40 µL of
l-DOPA, and 40 µL of tyrosinase (200 U/mL) in each well. Controls wells contained 10 µL of DMSO in
place of the sample. The absorbance was measured at 475 nm (endpoint) using a Synergy H1 Hybrid
Multi-Mode Reader (Biotek, Bad Friedrichshall, Germany). Inhibitory activity was determined as: %
Inhibition = (Absorbance Control − Absorbance Urolitihin A)/(Absorbance Control) × 100
2.3.2. Acetylcholinesterase (AChE) Inhibition
The inhibition of AChE was carried out in 96-well microplates, measuring the absorbance at
450 nm 11 times using a Synergy H1 Hybrid Multi-Mode Reader [22]. Each well contained 25 µL
of ATCI (15 mM) in MilliQ water, 50 µL of buffer B (50 mM Tris-HCl, pH = 8, 0.1% bovine serum),
125 µL of DTNB (3 mM) in buffer C (50 mM Tris-HCl, pH = 8, 100 mM NaCl, 20 mM MgCl2), and
25 µL of urolithin A at different concentrations in buffer A (50 mM Tris-HCl, pH = 8). Finally, 25 µL
of the enzyme (0.22 U/L) was added to the control and samples to complete the reaction. Blanks
contained 25 µL of buffer A instead of the enzyme. Galantamine (Sigma-Aldrich, St. Louis, MO,
USA), a drug used for Alzheimer’s disease, was assayed for comparative purposes as a reference
inhibitor. Percentages of AChE inhibition were calculated with the following formula: % Inhibition =
[1 − ((Inhibitory Slope)/(Control Slope))] × 100
2.3.3. Monoamine Oxidase A (MAO-A) Inhibition
The MAO-A inhibition assay was performed following a protocol described by Olsen et al. [23].
Here, 50 µL of urolithin A at different concentrations in DMSO, 50 µL chromogenic solution (417 mM
4-aminoantipyrine, 800 µM vanillic acid, 4 U/mL horseradish peroxidase in potassium phosphate
buffer pH = 7.6.), 100 µL of tyramine (300 µM), and 50 µL of MAO-A (8 U/mL) was supplemented into
the well. As a standard reference inhibitor, clorgyline was selected. Control wells contained 50 µL
of DMSO instead of urolithin A. The absorbance was read at 490 nm every 5 min over 30 min in a
Synergy H1 Hybrid Multi-Mode Reader (Biotek, Bad Friedrichshall, Germany). Percentages of MAO-A
inhibitions were calculated with the following formula: % Inhibition = [1 − ((Inhibitory Slope)/(Control
Slope))] × 100
2.4. Urolithin A and Its Role as a Direct Free Radical Scavenger
2.4.1. Oxygen Radical Antioxidant Capacity ORAC Assay
The capacity or urolithin A to scavenge peroxyl radicals was measured by the oxygen radical
antioxidant capacity (ORAC). Trolox was used as a reference standard for this assay. Therefore, data
were represented as µmol Trolox equivalents (TE)/mg sample. Different concentrations of urolithin A
(4.4 µM–4.4 mM) were dissolved in PBS and methanol (50:50) and placed into the wells. Urolithin A and
Trolox were incubated with fluorescein (70 mM) in 96-well plates at 37 ◦C. Finally, AAPH (12 mM) was
added and fluorescence was measured every 70 s for 1 h and 33 min at 485 nm (excitation) and 520 nm
(emission), in a Synergy H1 Hybrid Multi-Mode Reader (Biotek, Bad Friedrichshall, Germany) [24].
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2.4.2. Superoxide Radicals Generated by Xanthine/Xanthine Oxidase (X/XO) System
Another antioxidant test was performed in order to evaluate the antioxidant activity of urolithin
A using a more physiological system of superoxide radical generation [25]. Here, 22.8 µM nitroblue
tetrazolium (NBT), 90 µM xanthine, and 16 mM Na2CO3 were mixed in phosphate buffer (pH = 6.9).
Then, 240 µL of this cocktail was added to the well. Next, 30 µL of urolithin A and 30 µL of xanthine
oxidase (168 U/L) were added to start the reaction. Before measurement, the plate was incubated for
2 min at 37 ◦C. The superoxide radicals’ (O2−) scavenging activity was assessed spectrophotometrically
at 560 nm. The inhibitory activity of XO was also assayed spectrophotometrically at 295 nm. Gallic
acid was used as a reference antioxidant compound.
2.4.3. DPPH Radical Assay
Here, 2,2-diphenyl-1-picrylhydrazyl (DPPH) is a purple free radical. Antioxidant reducing
compounds are able to scavenge these free radicals, inducing a change in the color of this compound.
A methanolic stock solution of DPPH (0.11 mM) was prepared and 150 µL was added together with
150 µL of different urolithin A concentrations dissolved in MeOH. Ascorbic acid and gallic acid were
also measured as antioxidant standards. Control wells contained 150 µL of MeOH instead of urolithin
A. The plate was incubated for 30 min under dark conditions and measured at 517 nm [26]. Radical
scavenging capacity was calculated by the formula: % RSC = ((Absorbance Control−Absorbance
Urolithin A))/(Absorbance Control) × 100
2.5. Statistical Analysis
Each experiment was performed at least three times on different days and results were expressed
as the mean ± standard error (SE) of different assays. GraphPad Prism v.6 (GraphPad Software, San
Diego, CA, USA) was required to perform data analyses, nonlinear regressions, and statistics (such as
two-way ANOVA or one-way ANOVA). Statistical differences were detected by comparing IC50 values
of urolithin A and reference compounds using Student’s t-test.
3. Results
3.1. Cytoprotective Properties of Urolithin A in Neuro-2a Cells
3.1.1. Urolithin A Improves Mitochondrial Activity in Neuro-2a Cells Subjected to Oxidative Stress
(MTT Assay)
The viability of Neuro-2a cells was evaluated by the MTT assay. In this case, different physiological
concentrations of urolithin (0.5–50 µM) were tested in neurons for 24 h (Figure 2A). Results were
as expected because this range of concentration was non-toxic, as mitochondrial activity was not
significantly reduced.
The next purpose was to evaluate the protective effects of urolithin A on Neuro-2a cells using
hydrogen peroxide as a neurotoxic insult. Different conditions (100 µM to 1000 µM of H2O2) and
exposure times (15, 30, 45, 60 min) determined that incubation of hydrogen peroxide for 45 min at
250 µM was the most appropriate time period for inducing oxidative stress in N2a cells. Figure 2B
shows how urolithin A improves mitochondrial activity against hydrogen peroxide (250 µM) in this
cell line.
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Figure 2. Mitochondrial activity in Neuro-2a cells culture (MTT assay). (A) Cytotoxicity of Neuro-2a
cells after exposure to different concentrations of urolithin A. (B) Cytoprotective effects of urolithin A
versus hydrogen peroxide (250 µM). Note: * p < 0.05 versus H2O2; ## p < 0.01 versus control.
3.1.2. Urolithin A Decreases Intracellular ROS Production in Neuro-2a Cells Subjected to Oxidative
Stress (DCFHA-DA Assay)
Figure 3 shows the intracellular ROS production for 90 min. After 40 min of exposure, intracellular
ROS reached its highest formation (165%) for cells treated with hydrogen peroxide, whereas control
cells (non-treated) maintained a regular level close to 100%; cells stressed with hydrogen peroxide and
treated with urolithin A at different concentrations showed lower values for ROS production. Next,
the transition (50 min) showed a slight decrease in ROS formation for every treatment and maintained
a similar level for the rest of the experiment.
3.1.3. Urolithin A Decreases Lipid Peroxidation in Neuro-2a Cells Subjected to Oxidative Stress
(Thiobarbituric Acid Reactive Species, TBARS)
Figure 4 shows how thiobarbituric acid reactive species (TBARS) are generated. The results
are exhibited as a percentage over the control (100%). As expected, lipid peroxidation generated
by hydrogen peroxide was higher (147%) compared to control cells. Urolithin A response to lipid
peroxidation was more effective at lower concentrations (0.5 and 1 µM).
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Figure 4. Thiobarbituric acid reactive species (TBARS) formation in Neuro-2a cells. Note: * p < 0.05 
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3.1.4. Urolithin A Enhanced the Activity of Antioxidant Enzymes in Neuro-2a Cells Subjected to 
Oxidative Stress (CAT, SOD, GR, GPx) 
Results obtained after three replications in three different lysates showed a dose-dependent 
tendency of catalase for the treatments with urolithin A (Figure 5A). Surprisingly, the activity of the 
enzyme for the lowest concentration was even higher than the control. Therefore, the in vitro 
Figure 3. ROS production in Neuro-2a cells subjected to oxidative stress by hydrogen peroxide (250 µM)
and treatments with urolithin A (0.5–4 µM). Data are expressed as percentage over control cells and the
assay was carried out for 90 min in order to measure intracellular ROS production. Note: # p < 0.005
versus control; ## p < 0.001 versus control. Significant differences appeared at the starting point for
H2O2-N2a cells over control cells (p < 0.001). However, pre-treatments with 0.5 and 2 µM urolithin A at
0 and 10 min were associated with significant differences (p < 0.01). After 20 min, significant differences
were reached at 1 µM (p < 0.01). Finally, 4 µM of the antioxidant exhibited significant differences (p <
0.01) between 40 and 60 min. Urolithin A (2 µM) displayed a greater mitochondrial response than any
other co-treatment.
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Figure 4. Thiobarbituric acid reactive species (TBARS) formation in Neuro-2a cells. Note: * p < 0.05
versus H2O2.
3.1.4. Urolithin A Enhanced the Activity of Antioxidant Enzymes in Neuro-2a Cells Subjected to
Oxidative Stress (CAT, SOD, GR, GPx)
R sults obtained after three replications in three different lysates showed a dose-dependent
tendency of catalase for the treatments with urolithin A (Figure 5A). Surprisingly, the activity of
the enzyme for the lowest concentration was even higher than the control. Therefore, the in vitro
antioxidant effect observed for this metabolite may be more effective at lower doses. When the cells
were treated only with hydrogen peroxide, the response of catalas decreased compared to urolithin A
treatments, detecting significant differences against basal cells (p < 0.005) and the metabolite (p < 0.05;
0.01; 0.001).
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(C) Glutathione reductase activity. (D) Glutathione peroxidase activity. Note: * p < 0.05; ** p < 0.01;
*** p < 0.005; **** p < 0.001 versus H2O2; # p < 0.05 versus Control; ### p < 0.005 versus Control.
Different outcomes were found for the superoxide dismutase (SOD) enzyme (Figure 5B); a
dose-dependent te dency appeared up to 2 µM for SOD activity. Similar activity was observed at the
highest concentration as the lowest. Significant differences appeared at 2 µM (p < 0.05).
Comparable effects were obtained for GR and GPx activities (Figure 5C,D). Activities for 0.5 µM
urolithin A looked similar to control activities for both enzymes. Each concentration of the antioxidant
compound exerted significant differences for GR activity (p < 0.01; p < 0.005). However, significant
differences in GPx activity were only found at 2 µM urolithin A (p < 0.05).
3.1.5. Peroxiredoxins Expression
Figure 6 represents the expression of peroxiredoxins, a ubiquitous family of thiol-dependent
peroxidases involved in peroxide detoxification and redox signaling [27,28]. Prx1 was increased in a
dose-dependent manner over control cells (Figure 6A,B). Interestingly, mitochondrial Prx3 reached
higher levels at the lower urolithin concentration tested (Figure 6C,D). Urolithin A (1 and 2 µM)
treatments displayed significant differences in Prx1 expression in N2a cells over control cells (p < 0.05;
p < 0.01).
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Figure 6. Urolithin A-induced cytoprotection of Neuro-2a cells is mediated by induction of peroxiredoxin
1 and 3 (Prx1, Prx3). Prx 1 (A,B) and Prx 3 (C,D) expressions were determined by Western blot in 10 µg
of protein extract and expressed as Prx densitometry. Ponceau red staining of membranes prior to
blotting was performed to further check protein transfer and loading. Note: # p < 0.05 versus Control;
## p < 0.01 versus Control
3.2. Urolithin A Inhibits Oxidases (Monoamine Oxidase A and Tyrosinase)
As described above, the potential neuroprotective activity of urolithin A was tested on
different enzymes present in the central nervous system (tyrosinase, monoamine oxidase A, and
acetylcholinesterase). IC50 values were calculated by non-linear regression for kojic acid, clorgyline,
and galantamine reference inhibitors, respectively.
Figure 7 shows the profile of urolithin A as an enzyme inhibitor; in particular, Figure 7A compares
the reference inhibitor and urolithin against tyrosinase (IC50 values were 24.39 ± 5.97 µM and 71.44 ±
10.07 µM for kojic acid and urolithin A, respectively). Figure 7B shows how clorgyline and urolithin A
are able to inhibit MAO-A. In the case of the reference inhibitor, it IC50 value is relativ ly lower than
urolithin A (0.09 ± 0.02 µM and 29.41 ± 9.01 µM, respectively). Again, it is seen how the metab lite
draws a dose-dependent curve.
Finally, urolithin A was not considered as an inhibitor of AChE because very high non-physiological
concentrations (876 µM) were used to reach 50% of inhibition.
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3.3. The Role of Urolithin A as a Direct Free Radical Scavenger 
The direct antioxidant and reducing activities of urolithin A were measured by different free 
radical scavenging methods. To verify this fact, reference antioxidants such as gallic acid and ascorbic 
(vitamin C) acid were also tested and IC50 values were calculated (Figure 8). 
The antioxidant activity measured by the ORAC assay was 13.1 μmol TE/mg for urolithin A; this 
result reflects a great antioxidant capacity to neutralize peroxyl radicals compared to other high-
content urolithin A extracts, such as pomegranate, the activity of which was 0.49 μmol TE/mg. 
On the other hand, both in the inhibition of superoxide radicals and DPPH, urolithin A showed 
a dose-dependent curve reaching the maximum inhibition (100%). The reference compounds 
achieved better activity in terms of potency. IC50 values were 0.26 ± 0.21 μM for gallic acid and 5.01 ± 
5.01 μM for urolithin A (in the superoxide radical), while they were 3.10 ± 3.11 μM for gallic acid, 
14.81 ± 14.90 μM for ascorbic acid, and 152.66 ± 35.01 μM for urolithin A (DPPH radical). 
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3.3. The Role of Urolithin A as a Direct Free Radical Scavenger
The direct antioxidant and reducing activities of urolithin A were measured by different fre
radical scavenging methods. To verify this fact, reference antioxidants uch as gallic acid and ascorbic
(vitamin C) acid were also tested and IC50 values were calculated (Figure 8).
The antioxidant activity measured by the ORAC assay was 13.1 µmol TE/mg for urolithin A; this
result reflects a great antioxidant capacity to neutralize peroxyl adicals compared to other high-content
ur li hin A ex racts, such as pomegranate, the activity of which was 0.49 µmol TE/mg.
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4. Discussion 
Most of the studies involving natural products are performed with the original compounds 
found in the plant or food matrix, and very few are carried out with the metabolites obtained after 
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On the other hand, both in the inhibition of superoxide radicals and DPPH, urolithin A showed a
dose-dependent curve reaching the maximum inhibition (100%). The reference compounds achieved
better activity in terms of potency. IC50 values were 0.26 ± 0.21 µM for gallic acid and 5.01 ± 5.01 µM
for urolithin A (in the superoxide radical), while they were 3.10 ± 3.11 µM for gallic acid, 14.81 ±
14.90 µM for ascorbic acid, and 152.66 ± 35.01 µM for urolithin A (DPPH radical).
4. Discussion
Most of the studies involving natural products are performed with the original compounds found
in the plant or food matrix, and very few are carried out with the metabolites obtained after the
biotransformation in the body. Since ellagitannins are poorly absorbed in the gastrointestinal tract,
urolithins have been proposed as the bioactive metabolites responsible for the beneficial effects of
pomegranates and other plants containing ellagitannins. Pomegranate juice and extracts have exhibited
neuroprotective properties, so here we investigate whether urolithin A, one of the major intestinal
metabolites of ellagic acid, might act as a neurotherapeutic and antioxidant agent.
Neuro-2a is a neuroblastoma cell line derived from mice, which has been used because of its
ability to produce microtubular proteins. Few works have been done with urolithins using this cell line,
but it has been demonstrated that urolithin A protects against ischemic neuronal injury by activating
autophagy [29]. This research supports our results on mitochondrial activity, demonstrating that
urolithin A is not cytotoxic at this range of physiological concentrations (0.5–50 µM).
The antioxidant activity of urolithin A has already been established in different cell lines using
in vitro procedures [30–32]. However, we here investigate whether urolithin can be considered as
a neuroprotective agent due to its role as a direct free radical scavenger, as an indirect antioxidant
improving the physiological antioxidant defense system of the cells, and as an inhibitor of oxidases
such as monoamine oxidase A and tyrosinase.
Frequently, when the ROS and MDA levels decrease, the activity of the cytosolic enzymes
(superoxide dismutase, catalase) increases; previous experiments in HepG2 cells treated with urolithin
A and H2O2 have demonstrated that cells significantly increased SOD activity compared with cells
subjected to oxidative stress with H2O2 [30]; in fact, SOD activity was ameliorated by urolithin in
kidney cells from mice [33]. Computational studies performed with different pomegranate juice
constituents revealed that they can act as pro-oxidants or antioxidants. Molecular docking studies
seem to be controversial, as they have determined that urolithin A may inhibit cytosolic enzymes such
as catalase, superoxide dismutase, and glutathione [34]; however, urolithin A seems to improve the
activity of these enzymes in our present study. With the aim of elucidating molecular mechanisms
involved in the cytoprotective and antioxidant properties of urolithin A, peroxiredoxins expression
(Prx) was quantified in this work. These peroxiredoxins are antioxidant enzymes that catalyze the
reduction of hydroperoxide. Prx1 and Prx3 play a great role in response to oxidative stress. In this
way, the expression of Prx1 and Prx3 was increased when cells were treated with urolithin A, which
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translates into an antioxidant effect of urolithin A on Neuro-2a cells. Apart from the role of urolithin
A as a free radical scavenger, this phenolic compound seems to act in a more specific way through
the modulation of antioxidant enzymes. As observed above, urolithin A increased the expression
of peroxiredoxins; this fact may explain the cytoprotective properties of urolithin A improving cell
viability, decreasing ROS production, and increasing the activity of other physiological antioxidant
defense systems, such as catalase, SOD, or glutathione reductase and peroxidase. Other polyphenols,
such as resveratrol, have been described in the literature as antioxidant compounds with the ability to
induce these cytoprotective proteins known as peroxiredoxins [35]; nevertheless, this is the first time
that urolithin A is reported to increase the expression of peroxiredoxins 1 and 3.
This is also the first time that glutathione reductase and peroxidase activities were quantified in
neuronal cells subjected to urolithin A treatments. In order to assess this pro-oxidant or antioxidant
relationship of urolithin A, other researchers evaluated the in vitro antioxidant activity of the
metabolite in HepG2 cancer cells [36]; unexpectedly, urolithin A exerted a pro-oxidant effect on
these hepatoblastoma cells, however greater results were obtained in ORAC assay (6.67 ± 0.11).
Regarding oxygen radical absorbance capacity, mice treated with urolithin A exhibited significantly
different ORAC values after an hour of oral administration [37]. Nevertheless, urolithins may have
different antioxidant potency, as shown in previous studies [38], and the ORAC value of urolithin C
was lower than ours; the antioxidant properties derived from its role as a free radical scavenger were
also confirmed by the DPPH in other studies [39–41].
ROS generation is directly linked to neurodegenerative diseases, such as Alzheimer’s, Parkinson’s,
or Huntington’s diseases. In this way, after demonstrating the potential of this metabolite in
Neuro2-a cells, different bioassays were carried out involving CNS enzymatic targets known as
acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and tyrosinase; these enzymes are
considered pharmacological targets whose inhibition may lead to neuroprotective effects. Urolithin A
acted as an inhibitor of oxidase enzymes such as MAO-A and tyrosinase, thus preventing oxidative
damage of certain tissues. A human study in older adults with mild memory complaints suggests that
8 ounces of pomegranate juice taken daily over one-month improves verbal memory and alters neural
activity during a visual source memory task [42]. Synthetized urolithins have also demonstrated
comparable activity to AChE inhibitors such as rivastigmine, galantamine, and donepezil [43]. In silico
computational studies predicted that urolithins can penetrate the blood-brain barrier, preventing
β-amyloid fibrillation in a C. elegans model [44]. In addition, urolithin A has been identified as a proper
anti-inflammatory and anti-ageing compound [38]. Recently, 10 µM urolithin A was demonstrated to
possess depigmentation efficacy by suppressing tyrosinase activity, attenuating melanogenesis in B16
melanoma cells [45]. Tyrosinase has been recognised as a potential pharmacological target because
an excess of tyrosinase activity or dopamine may lead to neurotoxicity through dopamine quinone
formation; in this sense, tyrosinase inhibitors might have protective properties in neuronal cells.
MAO-A is responsible for the catalytic oxidative deamination of monoamines generating hydrogen
peroxide; for this reason, MAO-A inhibitors have been proposed as neuroprotective agents as well.
The inhibitory activity of pomegranate polyphenols on MAO-A has already been tested, which could
explain its effects in the CNS [22]; however, to the best of our knowledge this is the first report of
urolithin A as an antioxidant agent capable of neutralizing MAO-A oxidative reactions.
5. Conclusions
Urolithin A, a gastrointestinal metabolite from ellagitannins, is a promising therapeutic antioxidant
agent with potential pharmaceutical or food applications for the prevention of oxidative stress-associated
disorders, probably though the improvement of the cell antioxidant capacity by increasing the expression
of thiol-dependent peroxidases.
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